Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Paediatric rheumatic disease

Treatment of JIA in the biologic era: what are we waiting for?

Nature Reviews Rheumatology volume 10, pages 132–134 (2014)Cite this article

Subjects

If the use of the right treatment at the right time might 'cure' juvenile idiopathic arthritis, how do we determine the optimum timing of biologic therapy? The use of standardized consensus treatment plans in comparative effectiveness trials and of early testing for responsiveness to biologic treatment could lead the way.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ringold, S. et al. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.22259.

  2. Tynjälä, P. et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann. Rheum. Dis. 70, 1605–1612 (2011).

    Article  Google Scholar 

  3. Wallace, C. A. et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 64, 2012–2021 (2012).

    Article  Google Scholar 

  4. Ringold, S. et al. Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: a cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J. Rheumatol. 40, 936–942 (2013).

    Article  Google Scholar 

  5. Hinks, A. et al. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat. Genet. 45, 664–669 (2013).

    Article  CAS  Google Scholar 

  6. Beukelman, T. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken) 63, 465–482 (2011).

    Article  Google Scholar 

  7. Papsdorf, V. & Horneff, G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 50, 214–221 (2011).

    Article  CAS  Google Scholar 

  8. Lovell, D. J. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342, 763–769 (2000).

    Article  CAS  Google Scholar 

  9. Lovell, D. J. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359, 810–820 (2008).

    Article  CAS  Google Scholar 

  10. Ruperto, N. et al. Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal trial. Lancet 372, 383–391 (2008).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The author gives many thanks for critical reading of this commentary to J. E. McDonagh at the University of Birmingham and C. A. J. Ryder, P. Davis and M. Twilt at Birmingham Children's Hospital–NHS Trust, Birmingham, UK.

Author information

Authors and Affiliations

  1. Department of Paediatric Rheumatology, Institute of Child Health, 4th Floor Laboratories Block, Birmingham Children's Hospital–NHS Trust and University of Birmingham, Whittall Street, Birmingham, B4 6NH, UK

    Taunton R. Southwood

Authors
  1. Taunton R. Southwood
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taunton R. Southwood.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Southwood, T. Treatment of JIA in the biologic era: what are we waiting for?. Nat Rev Rheumatol 10, 132–134 (2014). https://doi.org/10.1038/nrrheum.2014.14

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2014.14

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing